ghrelin

ghrelin
  • 文章类型: Journal Article
    衰老和肥胖是肌肉减少症(RF)的协同危险因素。它们在减少肌肉肥胖(SO)中的关联增加了发病率和死亡率,但对SO诊断标准的共识有限。ESPEN和EASO发布了用于SO筛查(肥胖和临床SO怀疑)和诊断的共识算法[通过手握(HGS)和BIA的低肌肉质量],我们调查了它在老年人(>65岁)中的实施情况,以及SO相关的代谢RF[胰岛素抵抗(IR:HOMA)和血浆酰化(AG)和未酰化(UnAG)生长素释放肽,还从5年前的观察中评估了具有预测价值]。研究了意大利MoMa关于初级保健中代谢综合征的研究(n=76)中肥胖的老年人。61名筛查阳性的个体中有7名患有SO(SO+;队列的9%)。没有阴性筛查的个体有SO。SO+具有较高的IR,AG和血浆AG/UnAG比值(p<0.05vs阴性筛查和SO-),IR和ghrelin谱预测5年SO风险,与年龄无关,性别和BMI。当前的结果提供了第一个基于ESPEN-EASO算法的自由生活老年人的SO调查,肥胖人群的患病率为9%,算法敏感度为100%,在这种情况下,他们支持IR和血浆生长素释放肽作为SO风险因素。
    Aging and obesity are synergistic sarcopenia risk factors (RF). Their association in sarcopenic obesity (SO) enhances morbidity and mortality, but consensus on SO diagnostic criteria is limited. ESPEN and EASO issued a consensus algorithm for SO screening (obesity and clinical SO suspicion) and diagnosis [low muscle strength by hand-grip (HGS) and low muscle mass by BIA], and we investigated its implementation in older adults (>65-years), as well as SO-associated metabolic RF [insulin resistance (IR: HOMA) and plasma acylated (AG) and unacylated (UnAG) ghrelin, with predictive value also assessed from 5-year-prior observations]. Older adults with obesity from the Italian MoMa study on metabolic syndrome in primary care (n = 76) were studied. 7 of 61 individuals with positive screening had SO (SO+; 9 % of cohort). No individuals with negative screening had SO. SO+ had higher IR, AG and plasma AG/UnAG ratio (p < 0.05 vs negative screening and SO-), and both IR and ghrelin profile predicted 5-year SO risk independent of age, sex and BMI. The current results provide the first ESPEN-EASO algorithm-based investigation of SO in free-living older adults, with 9 % prevalence in those with obesity and 100 % algorithm sensitivity, and they support IR and plasma ghrelin profile as SO risk factors in this setting.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    胃源的辛酸化肽ghrelin于1999年被发现,被认为是生长激素促分泌素受体(GHSR)的内源性激动剂。随后,ghrelin不仅在控制生长激素分泌方面发挥关键作用,还有各种其他生理功能,包括,但不限于,食物摄入量,与奖励相关的行为,葡萄糖稳态和胃肠道运动。重要的是,一种非酰化形式的生长素释放肽,去酰基-生长素释放肽,也可以在生物样品中检测到。去酰基-生长素释放肽,然而,在生理水平上不与GHSR结合,它的生理作用仍然没有ghrelin那么好。Ghrelin和去酰基-ghrelin目前在文献中使用许多不同的术语,强调需要一致的命名法。用于指定ghrelin的术语的可变性不仅会导致混乱,还有误解,特别是对于那些不太熟悉ghrelin文学的人。因此,我们在对ghrelin文献有贡献的专家中进行了一项调查,旨在确定是否可以达成共识。根据这一共识的结果,我们建议使用术语“ghrelin”和“去酰基-ghrelin”来指代激素本身及其非酰化形式,分别。根据这一共识的结果,我们进一步建议使用术语“GHSR”作为受体,和“LEAP2”用于肝脏表达的抗菌肽2,这是一种最近公认的内源性GHSR拮抗剂/反向激动剂。
    The stomach-derived octanoylated peptide ghrelin was discovered in 1999 and recognized as an endogenous agonist of the growth hormone secretagogue receptor (GHSR). Subsequently, ghrelin has been shown to play key roles in controlling not only growth hormone secretion, but also a variety of other physiological functions including, but not limited to, food intake, reward-related behaviors, glucose homeostasis and gastrointestinal tract motility. Importantly, a non-acylated form of ghrelin, desacyl-ghrelin, can also be detected in biological samples. Desacyl-ghrelin, however, does not bind to GHSR at physiological levels, and its physiological role has remained less well-characterized than that of ghrelin. Ghrelin and desacyl-ghrelin are currently referred to in the literature using many different terms, highlighting the need for a consistent nomenclature. The variability of terms used to designate ghrelin can lead not only to confusion, but also to miscommunication, especially for those who are less familiar with the ghrelin literature. Thus, we conducted a survey among experts who have contributed to the ghrelin literature aiming to identify whether a consensus may be reached. Based on the results of this consensus, we propose using the terms \"ghrelin\" and \"desacyl-ghrelin\" to refer to the hormone itself and its non-acylated form, respectively. Based on the results of this consensus, we further propose using the terms \"GHSR\" for the receptor, and \"LEAP2\" for liver-expressed antimicrobial peptide 2, a recently recognized endogenous GHSR antagonist/inverse agonist.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    在慢性阻塞性肺疾病(COPD)患者中,骨骼肌功能障碍是一种主要的共病,对他们的运动能力和生活质量产生负面影响。在目前的指导方针中,纳入了有关COPD肌肉功能障碍各个方面的最新文献.建议的分级,评估,发展,和评估(等级)量表已用于对不同特征提出基于证据的建议。与对照人口相比,三分之一的COPD患者股四头肌肌力下降25%,甚至在他们疾病的早期阶段。尽管呼吸肌和肢体肌肉都发生了改变,后者通常受到更严重的影响。COPD肌肉功能障碍的病因涉及许多因素和生物学机制。为了诊断和评估呼吸和四肢肌肉(外周)的肌肉功能障碍程度,提出了几种测试。以及确定患者的运动能力(六分钟步行测试和循环测功)。还描述了当前可用的治疗策略,包括不同的训练方式以及药理和营养支持。
    In patients with chronic obstructive pulmonary disease (COPD), skeletal muscle dysfunction is a major comorbidity that negatively impacts their exercise capacity and quality of life. In the current guidelines, the most recent literature on the various aspects of COPD muscle dysfunction has been included. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) scale has been used to make evidence-based recommendations on the different features. Compared to a control population, one third of COPD patients exhibited a 25% decline in quadriceps muscle strength, even at early stages of their disease. Although both respiratory and limb muscles are altered, the latter are usually more severely affected. Numerous factors and biological mechanisms are involved in the etiology of COPD muscle dysfunction. Several tests are proposed in order to diagnose and evaluate the degree of muscle dysfunction of both respiratory and limb muscles (peripheral), as well as to identify the patients\' exercise capacity (six-minute walking test and cycloergometry). Currently available therapeutic strategies including the different training modalities and pharmacological and nutritional support are also described.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号